Third Harmonic Bio, Inc. (THRD) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
THRD currently has 45.1M outstanding shares. with moderate dilution risk from 10.4M authorized shares representing 22.9% potential dilution. The company has diluted shareholders by 14.02% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Jul 31, 2025 |
POS AM filing: This is a post-effective amendment to deregister securities from a previous S-3 filing due to the company's plan of dissolution. |
45M | 10M |
| May 08, 2025 |
10-Q filing | 45.1M shares outstanding |
45M | 34M |
| Mar 27, 2025 |
10-K filing | 45.1M shares outstanding |
45M | 34M |
| Nov 07, 2024 |
10-Q filing | 45.1M shares outstanding |
45M | 34M |
| Aug 08, 2024 |
10-Q filing | 39.6M shares outstanding |
40M | 34M |
| May 15, 2024 |
10-Q filing | 39.4M shares outstanding |
39M | 34M |
| Mar 26, 2024 |
10-K filing | 40.7M shares outstanding |
41M | 34M |
| Nov 09, 2023 |
10-Q filing | 40.4M shares outstanding |
40M | 34M |
| Oct 02, 2023 |
S-3 filing: Third Harmonic Bio, Inc. may offer up to $400.0 million aggregate dollar amount of shares of their common stock or preferred stock, debt securities, warrants to purchase their common stock, preferred stock or debt securities, subscription rights to purchase their common stock, preferred stock or debt securities and/or units consisting of some or all of these securities, in any combination. |
40M | 34M |
| Aug 10, 2023 |
10-Q filing | 40.4M shares outstanding |
40M | 10M |
| May 11, 2023 |
10-Q filing | 40.4M shares outstanding |
40M | 10M |
| Mar 29, 2023 |
10-K filing | 40.3M shares outstanding |
40M | 10M |
| Nov 09, 2022 |
10-Q filing | 40.5M shares outstanding |
41M | 10M |
| Sep 08, 2022 |
S-1/A filing: This is an S-1/A filing for a company offering 9,000,000 shares of common stock at an assumed initial public offering price of $17.00 per share, with an underwriter's over-allotment option of 1,350,000 shares. The company intends to list its common stock on Nasdaq under the symbol "THRD." |
28M | 10M |
| Aug 23, 2022 |
S-1 filing: This S-1 filing is for an initial public offering of common stock. The company intends to use the net proceeds from this offering to advance the clinical development of THB001 for the treatment of urticaria and asthma, fund further development or acquisition of future programs, and for working capital and other general corporate purposes. |
63M | 0 |